Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 2
1999 1
2002 1
2003 1
2004 3
2005 4
2006 2
2007 2
2008 10
2009 5
2010 9
2011 16
2012 15
2013 14
2014 10
2015 14
2016 14
2017 7
2018 15
2019 8
2020 11
2021 15
2022 9
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O. You B, et al. Among authors: tod m. Clin Cancer Res. 2020 Sep 1;26(17):4625-4632. doi: 10.1158/1078-0432.CCR-20-0054. Epub 2020 Mar 24. Clin Cancer Res. 2020. PMID: 32209570 Clinical Trial.
Azithromycin for COVID-19: More Than Just an Antimicrobial?
Bleyzac N, Goutelle S, Bourguignon L, Tod M. Bleyzac N, et al. Among authors: tod m. Clin Drug Investig. 2020 Aug;40(8):683-686. doi: 10.1007/s40261-020-00933-3. Clin Drug Investig. 2020. PMID: 32533455 Free PMC article. No abstract available.
Pharmacodynamic models for discrete data.
Paule I, Girard P, Freyer G, Tod M. Paule I, et al. Among authors: tod m. Clin Pharmacokinet. 2012 Dec;51(12):767-86. doi: 10.1007/s40262-012-0014-9. Clin Pharmacokinet. 2012. PMID: 23179578 Review.
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Lemaitre F, Solas C, Grégoire M, Lagarce L, Elens L, Polard E, Saint-Salvi B, Sommet A, Tod M, Barin-Le Guellec C; French Society of Pharmacology, Therapeutics (SFPT), the International Association of Therapeutic Drug Monitoring, Clinical Toxicology (IATDMCT). Lemaitre F, et al. Among authors: tod m. Fundam Clin Pharmacol. 2020 Oct;34(5):530-547. doi: 10.1111/fcp.12586. Epub 2020 Jul 24. Fundam Clin Pharmacol. 2020. PMID: 32603486 Free PMC article. Review.
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, Fontaine J, Péron J, Maillet D, Tartas S, Bonnin N, Trillet-Lenoir V, Colomban O, Augu-Denechere D, Freyer G, Tod M. Puszkiel A, et al. Among authors: tod m. Cancer Chemother Pharmacol. 2023 May;91(5):413-425. doi: 10.1007/s00280-023-04520-z. Epub 2023 Apr 3. Cancer Chemother Pharmacol. 2023. PMID: 37010549 Clinical Trial.
169 results